Adaptive Biotechnologies   Report issue

For profit Phase 2
Founded: Seattle WA United States (2009)

Organization Overview

First Clinical Trial
2020
NCT04419519
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Adaptive | Adaptive Biotechnologies

Active Ingredients

Drugs in Phase 2 Trials (1)

venetoclax (venclexta) (1 trial)

Drugs in Other Trials (1)

Key: Adaptive Biotechnologies (0) Acquired (1)

fludeoxyglucose f-18 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Multiple Myeloma (Phase 3)

Neoplasm, Residual (Phase 2)

Neoplasms, Plasma Cell (Phase 3)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2